MedTrace Logo

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2025-12-23

No results posted yet for this study

Summary

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Conditions

Interventions

DRUG

TORL-1-23

2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

TORL-1-23

3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

TORL-1-23

3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

Pegfilgrastim (drug)

6.0 mg subcutaneous injection on Day 4 of each cycle.

Sponsors & Collaborators

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • TORL Biotherapeutics, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2027-10-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Ireland
  • Italy
  • Singapore
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06690775 on ClinicalTrials.gov